We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
European regulators are proposing a series of indirect methods for driving down prescription drug costs without stepping outside the science-focused parameters of their roles. Read More
A planned settlement between Aegerion Pharmaceuticals and federal officials will require the company to shell out $40 million and plead guilty to two misdemeanor violations of the FD&C Act, the company disclosed Friday. Read More
The UK’s National Institute for Health and Care Excellence says it will not recommend Bristol-Myers Squibb’s Opdivo, casting doubt on the drug’s cost-effectiveness for people with locally advanced or metastatic non-squamous, non-small-cell lung cancer after chemotherapy. Read More